The DOI matches its Crossref record; 278 of the 278 references it cites were found in a registry or an index.
Nitric oxide, a double edged sword in cancer biology: Searching for therapeutic opportunities
Abstract
Nitric oxide (NO) is a pleiotropic molecule critical to a number of physiological and pathological processes. The last decade has witnessed major advances in dissecting NO biology and its role in cancer pathogenesis. However, the complexity of the interactions between different levels of NO and several aspects of tumor development/progression has led to apparently conflicting findings. Furthermore, both anti‐NO and NO‐based anticancer strategies appear effective in several preclinical models. This paradoxical dichotomy is leaving investigators with a double challenge: to determine the net impact of NO on cancer behavior and to define the therapeutic role of NO‐centered anticancer strategies. Only a comprehensive and dynamic view of the cascade of molecular and cellular events underlying tumor biology and affected by NO will allow investigators to exploit the potential antitumor properties of drugs interfering with NO metabolism. Available data suggest that NO should be considered neither a universal target nor a magic bullet, but rather a signal transducer to be modulated according to the molecular makeup of each individual cancer and the interplay with conventional antineoplastic agents. © 2006 Wiley Periodicals, Inc. Med Res Rev, 27, No. 3, 317–352, 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 201–278 of 278
Carlo, E. D., Comes, A., Basso, S., Ambrosis, A. D., Meazza, R., Musiani, P., Moelling, K., Albini, A., & Ferrini, S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.6.3111 · Cited by 75
Li, L., Feng, Z., & Porter, A. G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310415200 · Cited by 74
Kim, J., Ohshima, S., Pediaditakis, P., & Lemasters, J. J. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.09.014 · Cited by 73
Qiu, H., Orr, F. W., Jensen, D., Wang, H. H., McIntosh, A. R., Hasinoff, B. B., Nance, D. M., Pylypas, S. P., Qi, K., Song, C. H., et al. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63835-7 · Cited by 73
Park, S., Lee, S., Song, S., Heo, D., Park, B., Lee, D., Kim, K., & Sung, M. (2003) · International Journal of Cancer · doi:10.1002/ijc.11498 · Cited by 72
Lee, Y. J., Lee, K. H., Kim, H.-R. C., Jessup, J. M., Seol, D., Kim, T., Billiar, T. R., & Song, Y. K. (2001) · Oncogene · doi:10.1038/sj.onc.1204225 · Cited by 72
Nitric oxide and inflammation: The answer is blowing in the wind
Lundberg, J. O., Lundberg, J. M., Alving, K., & Weitzberg, E. (1997) · Nature Medicine · doi:10.1038/nm0197-30 · Cited by 71
Nitric oxide of human colorectal adenocarcinoma cell lines promotes tumour cell invasion
Siegert, A., Rosenberg, C., Schmitt, W., Denkert, C., & Hauptmann, S. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600224 · Cited by 71
Role of Nitric Oxide in Tumor Angiogenesis
Morbidelli, L., Donnini, S., & Ziche, M. (2004) · Cancer treatment and research · doi:10.1007/978-1-4419-8871-3_11 · Cited by 70
Nitric oxide priming protects nitric oxide-mediated apoptosis via HEME OXYGENASE-1 induction
Choi, B., Pae, H., & Chung, H. (2003) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(03)00064-9 · Cited by 70
Secchiero, P., Gonelli, A., Celeghini, C., Mirandola, P., Guidotti, L., Visani, G., Capitani, S., & Zauli, G. (2001) · Blood · doi:10.1182/blood.v98.7.2220 · Cited by 69
Nitric Oxide Disrupts H2O2-dependent Activation of Nuclear Factor κB
Garbán, H., & Bonavida, B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008471200 · Cited by 68
Wang, Z., Cook, T., Alber, S. M., Liu, K., Kovesdi, I., Watkins, S. C., Yoram Vodovotz, B., Billiar, T. R., & Blumberg, D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1307 · Cited by 67
Binder, C. R., Schulz, M., Hiddemann, W., & Oellerich, M. (1999) · PubMed · Cited by 65
Tatemichi, M., Sawa, T., Gilibert, I., et al. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.09.002 · Cited by 64
Medeiros, R., Morais, A., Vasconcelos, A., Costa, S., Pinto, D., Oliveira, J., Ferreira, P., & Lopes, C. (2002) · PubMed · Cited by 62
Nitric oxide‐mediated regulation of hypoxia‐induced B16F10 melanoma metastasis
Postovit, L.-M. M., ADAMS, M. A., Lash, G. E., Heaton, J. P. W., & Graham, C. H. (2003) · International Journal of Cancer · doi:10.1002/ijc.11556 · Cited by 61
Implications of apoptosis regulators in tumorigenesis
Malaguarnera, L. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031774.32572.df · Cited by 61
Nosho, K., Yamamoto, H., Adachi, Y., Endo, T., Hinoda, Y., & Imai, K. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602442 · Cited by 61
Pan, S., Guh, J., Peng, C.-Y., Wang, S., Chang, Y.-L., Cheng, F., Chang, J.-H., Kuo, S., Lee, F., & Teng, C. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085126 · Cited by 61
Wenzel, U., Kuntz, S., de Sousa, U. L. J., & Daniel, H. (2003) · International Journal of Cancer · doi:10.1002/ijc.11294 · Cited by 60
The Past Decade of Experience With Isolated Hepatic Perfusion
Grover, A. C., & Alexander, H. R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-6-653 · Cited by 58
Chen, T., Nines, R. G., Peschke, S. M., Kresty, L. A., & Stoner, G. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0302 · Cited by 56
Wang, B., Wei, D., Crum, V. E., Richardson, E. L., XIONG, H., Luo, Y., Huang, S., Abbruzzese, J. L., & Xie, K. (2003) · Oncogene · doi:10.1038/sj.onc.1206386 · Cited by 54
Arginine metabolic pathways involved in the modulation of tumor‐induced angiogenesis by macrophages
Davel, L., Jasnis, M. A., de la Torre, E., Gotoh, T., Diament, M., Magenta, G., de Lustig, E. S., & Sales, M. E. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03682-7 · Cited by 53
Chang, C., Chen, W., Lin, H., Wu, C.-C., & Wang, C. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i15.2232 · Cited by 52
Xu, L., Xie, K., & Fidler, I. J. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.18-2699 · Cited by 52
Witherell, H., Hiatt, R., Replogle, M. L., & Parsonnet, J. (1998) · PubMed · Cited by 52
eNOS protects prostate cancer cells from TRAIL-induced apoptosis
Tong, X., & Li, H. (2004) · Cancer Letters · doi:10.1016/j.canlet.2003.12.021 · Cited by 49
Isolated limb perfusion in locally advanced cutaneous melanoma
Rossi, C. R., Foletto, M., Pilati, P., et al. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.34119 · Cited by 47
Elk-3 Is a Transcriptional Repressor of Nitric-oxide Synthase 2
Chen, Y., Layne, M. D., Chung, S. W., 江島, 邦., Baron, R. M., Yet, S., & Perrella, M. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308179200 · Cited by 47
Tumor Cytotoxicity by Endothelial Cells
Ortega, Á., Carretero, J., Obrador, E., Gambini, J., Asensi, M. A., Rodilla, V., & Estrela, J. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207140200 · Cited by 46
Nitric Oxide Confers Therapeutic Activity to Dendritic Cells in a Mouse Model of Melanoma
Perrotta, C., Falcone, S., Capobianco, A., Camporeale, A., Sciorati, C., Palma, C. D., Pisconti, A., Rovere, P. Q., Bellone, M., Manfredi, A. A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0668 · Cited by 46
Nitric oxide does not mediate but inhibits transformation and tumor phenotype.
Dhar, A., Brindley, J. M., Stark, C., Citro, M. L., Keefer, L. K., & Colburn, N. H. (2003) · PubMed · Cited by 46
Nitric Oxide Inhibits Inducible Nitric Oxide Synthase mRNA Expression in RAW 264.7 Macrophages
Hinz, B., Brune, K., & Pahl, A. M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2632 · Cited by 44
Jarry, A., Charrier, L., Bou‐Hanna, C., Devilder, M., Crussaire, V., Denis, M. G., Vallette, G., & LABOISSE, C. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0254 · Cited by 44
Bruns, C. J., Shinohara, H., Harbison, M. T., Davis, D. W., Nelkin, G. M., Killion, J. J., McConkey, D. J., Dong, Z., & Fidler, I. J. (2000) · PubMed · Cited by 42
Kuchel, J. M., Barnetson, R. S., & Halliday, G. M. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12415.x · Cited by 42
Implications of the zinc‐finger motif found in the DNA‐binding domain of the human XPA protein
Morita, E. H., Ohkubo, T., Kuraoka, I., Shirakawa, M., Tanaka, K., & Morikawa, K. (1996) · Genes to Cells · doi:10.1046/j.1365-2443.1996.d01-252.x · Cited by 42
Park, S. W., & Wei, L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303306200 · Cited by 41
Paolucci, C., Burastero, S. E., Rovere, P. Q., Palma, C. D., Falcone, S., Perrotta, C., Capobianco, A., Manfredi, A. A., & Clementi, E. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0902447 · Cited by 41
Kaku, Y., Nanri, H., 崎村, 知., 江島, 邦., Kuroiwa, A., & Ikeda, M. (1997) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(96)00156-5 · Cited by 41
Mendes, R. V., Martins, A. R., Nucci, G. D., Murad, F., & Soares, F. A. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01189.x · Cited by 41
Overexpression of iNOS gene suppresses the tumorigenicity and metastasis of oral cancer cells.
Harada, K., Supriatno, Kawaguchi, S.-I., Onoue, T., Yoshida, H., & Sato, M. (2004) · PubMed · Cited by 41
Suppression of azoxymethane-induced colonic aberrant crypt foci by a nitric oxide synthase inhibitor
Kawamori, T. (2000) · Cancer Letters · doi:10.1016/s0304-3835(99)00310-9 · Cited by 39
The Moving Frontier in Nitric Oxide–Dependent Signaling
Nathan, C. (2004) · Science s STKE · doi:10.1126/stke.2572004pe52 · Cited by 38
Hegardt, P., Widegren, B., & Sjögren, H. O. (2000) · Cellular Immunology · doi:10.1006/cimm.2000.1625 · Cited by 38
Zhang, X. M., & Xu, Q. (2001) · Melanoma Research · doi:10.1097/00008390-200112000-00002 · Cited by 37
Inactivated tumor suppressor Rb by nitric oxide promotes mitosis in human breast cancer cells
Radisavljevic, Z. M. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20063 · Cited by 35
Weninger, W., Rendl, M., Pammer, J., Mildner, M., Tschugguel, W., Schneeberger, C., Stürzl, M., & Tschachler, E. (1998) · PubMed · Cited by 34
Polymorphisms of the endothelial nitric oxide synthase gene in women with vulvar cancer
Riener, E., Hefler, L., Grimm, C., Galid, A., Zeillinger, R., TONGCACSIRE, D., Gitsch, G., Leodolter, S., & Tempfer, C. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.03.030 · Cited by 33
Zhang, X., Chen, Z., Huang, H., Gordon, J., & Xiang, J. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)02164-1 · Cited by 33
Hegardt, P., Widegren, B., Li, L., Sjögren, B., Kjellman, C., Sur, I., & Sjögren, H. O. (2001) · Cancer Immunology Immunotherapy · doi:10.1007/s002620100230 · Cited by 32
Mutations induced by reactive nitrogen oxide species in the supF forward mutation assay
Routledge, M. N. (2000) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(00)00018-x · Cited by 31
Ichinoe, M., Mikami, T., Shiraishi, H., & Okayasu, I. (2004) · Histopathology · doi:10.1111/j.1365-2559.2004.02031.x · Cited by 31
Selleri, C., Maciejewski, J. P., Montuori, N., Ricci, P., Visconte, V., Serio, B., Luciano, L., & Rotoli, B. (2003) · Blood · doi:10.1182/blood-2003-01-0178 · Cited by 30
Deininger, M. H., Wybranietz, W. A., Graepler, F., Lauer, U. M., Meyermann, R., & Schluesener, H. J. (2003) · The FASEB Journal · doi:10.1096/fj.02-1118com · Cited by 28
Inhibition of peroxynitrite-mediated tyrosine nitration by a novel pyrrolopyrimidine antioxidant
Rohn, T. T., & Quinn, M. T. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00399-9 · Cited by 28
Shinoda, J., McLaughlin, K. E., Bell, H. S., et al. (2003) · Glia · doi:10.1002/glia.10200 · Cited by 27
Nitrotyrosine in esophageal squamous cell carcinoma and relevance to p53 expression
Kato, H., Miyazaki, T., Yoshikawa, M., Nakajima, M., Fukai, Y., Tajima, K., Masuda, N., Tsutsumi, S., Tsukada, K., Nakajima, T., et al. (2000) · Cancer Letters · doi:10.1016/s0304-3835(00)00358-x · Cited by 27
Induction of Nitric Oxide Production by Natural Killer Cells: Its Role in Tumor Cell Death
Jyothi, M. D., & Khar, A. (1999) · Nitric Oxide · doi:10.1006/niox.1999.0243 · Cited by 27
Schleiffer, R., Duranton, B., Gossé, F., Bergmann, C., & Raul, F. (2000) · Nitric Oxide · doi:10.1006/niox.2000.0310 · Cited by 26
Hu, D., Dyke, S. O. M., Moore, A. M., Thomsen, L. L., & Brindle, K. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1807 · Cited by 24
Targeted therapy for colorectal cancer: mapping the way
D, S. M. M., Lise, M., & Nitti, D. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.05.002 · Cited by 24
Self-citationYamamoto, T., Terada, N., Seiyama, A., Nishizawa, Y., Akedo, H., & Kosaka, H. (1998) · International Journal of Cancer · Cited by 21
Kelley, S. T., Menon, C., Buerk, D. G., et al. (2002) · Surgery · doi:10.1067/msy.2002.125713 · Cited by 20
Kawakami, K., Kawakami, M., Husain, S. R., & Puri, R. K. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301956 · Cited by 19
Immunohistochemical expression of cytokine induced nitric oxide synthase in colorectal carcinoma
Nozoe, T., Yasuda, M., Honda, M., Inutsuka, S., & Korenaga, D. (2002) · Oncology Reports · doi:10.3892/or.9.3.521 · Cited by 19
D, S. M. M., Provenzano, M., Rossi, C. R., Pilati, P., Scalerta, R., Lise, M., & Nitti, D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0791 · Cited by 19
Self-citationUneda, S., Hata, H., Matsuno, F., Nagasaki, A., Harada, N., Mitsuya, Y., Matsuzaki, H., & Mitsuya, H. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04078.x · Cited by 18
Vascularization of Melanoma by Mobilization and Remodeling of Preexisting Latent Vessels to Patency
Lu, W., & Schroit, A. J. (2005) · Cancer Research · doi:10.1158/0008-5472.913.65.3 · Cited by 17
Zaręba, M., Niziolek, M., Korytowski, W., & Girotti, A. W. (2004) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2004.11.007 · Cited by 17
Kook, H., Ahn, K. Y., Lee, S. E., Na, H. S., & Kim, K. K. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00967-0 · Cited by 17
Kai, H., Ito, M., Kitadai, Y., et al. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01965.x · Cited by 16
Lavagna, C., Soldato, P. D., Burgaud, J., et al. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481750 · Cited by 13
Downie, I. P., Umar, T., Boote, D. J., Mellor, T. K., Hoffman, G., & Brennan, P. A. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2003.12.030 · Cited by 8
Kita, Y., Hirasawa, Y., Kato, Y., Ohkubo, K., Ohno, M., Nishino, S., Kato, M., & Fukuyama, S. (1997) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199708000-00011 · Cited by 6
(2001) · PubMed
Cited by
Gold nanoparticles in delivery applications☆
GHOSH, P., HAN, G., DE, M., KIM, C., & ROTELLO, V (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.016 · Cited by 2,694
Nitric oxide release: Part II. Therapeutic applications
Carpenter, A. W., & Schoenfisch, M. H. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15273h · Cited by 964
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 702
Metabolites and the Tumour Microenvironment: From Cellular Mechanisms to Systemic Metabolism
Elia, I., & Haigis, M. C. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00317-z · Cited by 651
A Review on the Synthesis and Functionalization of Gold Nanoparticles as a Drug Delivery Vehicle
Amina, S. J., & Guo, B. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s279094 · Cited by 561
Metadata
- Authors
- Mocellin, S., Bronte, V., & Nitti, D.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2006-09-21
- Volume
- 27
- Issue
- 3
- Pages
- 317-352
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2098652851
- Cited by
- 478
- References
- 278
- FWCI
- 10.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.